SPAG9 and neoplasm: To further confirm the circulating anti-SPAG9 antibodies in the bladder TCC patients’ sera, Western blot was done using recombinant SPAG9 protein (Figure 5B) which revealed that immunoreactivity was found in 77% of total bladder TCC patients irrespective of tumor stages (Table 1).